Botulinum Toxin Application in the Medical Aesthetics Industry

A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".

Deadline for manuscript submissions: 15 August 2025 | Viewed by 4380

Special Issue Editor


E-Mail Website
Guest Editor
Department of Dermatology, Sungkyunkwan University School of Medicine, 2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do, Republic of Korea
Interests: aesthetic medicine; anti-aging; botulinum neurotoxin; dermatologic surgery; regenerative dermatology

Special Issue Information

Dear Colleagues,

Botulinum neurotoxin injection is one of the most massively used modalities in aesthetic medicine and surgery. Currently, there are various injectable botulinum neurotoxin products worldwide. Different products show different pharmacologic characteristics, while many features are shared. Some products eliminate non-toxin proteins to reduce risk of antibody formation. Some new products exist in ready-to-inject liquid form. The diversity of the botulinum neurotoxin products in the market suggests that there should be a summary to characterise and compare each product. This Special Issue aims to provide an update on the current status of botulinum toxin products in the field and their clinical applications in the context of aesthetic medicine and surgery.

Potential topics include (but are not limited to) the following:

- Review of the product comparison;

- Clinical consensus and practice guidelines on the use a specific neurotoxin product;

- Off-facial or non-conventional aesthetic indications of botulinum neurotoxin;

- Position statements on medical, legal, and cultural issues related to aesthetic uses of botulinum toxin;

- Early reports on the clinical use of newly developed products;

- Development of new botulinum toxin formulations;

- Market analysis and forecast.

Dr. Nark-Kyoung Rho
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • botulinum neurotoxin
  • medical aesthetics
  • product comparison
  • product development
  • clinical consensus
  • practice guideline
  • position statement
  • off-facial aesthetic indications
  • combined treatments with other modalities
  • novel delivery methods
  • new anatomical perspectives
  • immunogenicity

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 2449 KiB  
Article
Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19
by Hye Sung Han, Won-Serk Kim, Yangwon Lee, Chong-Hyun Won, Wooshun Lee, Sun Young Choi and Beom Joon Kim
Toxins 2025, 17(4), 160; https://doi.org/10.3390/toxins17040160 - 23 Mar 2025
Viewed by 705
Abstract
MBA-P01 is a newly developed botulinum toxin A (BoNT-A) product designed to provide similar clinical effects as OnabotulinumtoxinA (ONA-BoNT-A), thereby providing an alternative treatment option for glabellar lines. It is another holotoxin preparation containing BoNT-A1. This randomized, double-blind, active-controlled, multi-center, Phase III clinical [...] Read more.
MBA-P01 is a newly developed botulinum toxin A (BoNT-A) product designed to provide similar clinical effects as OnabotulinumtoxinA (ONA-BoNT-A), thereby providing an alternative treatment option for glabellar lines. It is another holotoxin preparation containing BoNT-A1. This randomized, double-blind, active-controlled, multi-center, Phase III clinical trial aimed to evaluate the efficacy and safety of MBA-P01 compared with OnabotulinumtoxinA (ONA-BoNT-A). In total, 318 participants were enrolled and received 20 units of MBA-P01 or ONA-BoNT-A on the forehead and glabella. At the 4-week assessment, the primary endpoint revealed no significant difference in the improvement rate of glabellar wrinkles between the two groups, confirming the non-inferiority of MBA-P01 to ONA-BoNT-A. Furthermore, some evaluation variables showed higher improvement rates for MBA-P01 than for ONA-BoNT-A. Adverse reactions and other safety analysis results were considered acceptable. Interestingly, a subgroup analysis of patients with the coronavirus disease (COVID-19) showed that the duration of BoNT-A treatment was shorter among those who contracted COVID-19 after BoNT-A treatment compared with those who have not. The limitations of this study include the predominance of female participants and the exclusive enrollment of Korean patients. MBA-P01 is expected to be clinically useful in terms of the efficient and safe reduction of glabellar wrinkles, which will provide patients with additional treatment options. Full article
(This article belongs to the Special Issue Botulinum Toxin Application in the Medical Aesthetics Industry)
Show Figures

Figure 1

Other

Jump to: Research

23 pages, 8585 KiB  
Perspective
Consensus on the Cosmetic Use of a Novel Botulinum Neurotoxin Type A Product (NEWLUX®) for Facial Expression Muscles: 2024 Guidelines and Discussions by Korean Experts
by Nark-Kyoung Rho, Gee Young Bae, Moon Seop Choi, Woon-Kyong Chung, Hoon-Young Kim, Hyoung Moon Kim, Hong-Ki Lee, Yong Woo Lee, Wook Oh and Wu-Chul Song
Toxins 2025, 17(2), 61; https://doi.org/10.3390/toxins17020061 - 29 Jan 2025
Viewed by 3689
Abstract
Background: Botulinum neurotoxin type A (BoNTA) is widely used in aesthetic facial rejuvenation medicine. The exponential growth in using BoNTA for cosmetic purposes in Korea necessitates an update to the existing practice guidelines, building upon the consensus established by Korean experts in 2013. [...] Read more.
Background: Botulinum neurotoxin type A (BoNTA) is widely used in aesthetic facial rejuvenation medicine. The exponential growth in using BoNTA for cosmetic purposes in Korea necessitates an update to the existing practice guidelines, building upon the consensus established by Korean experts in 2013. Aims: This work aims to provide an updated Korean consensus guideline for the safe and effective use of a novel BoNTA product (NEWLUX) for facial expression muscles. Methods: A panel of ten Korean experts in dermatology, plastic surgery, aesthetic medicine, and clinical anatomy convened in February 2024. They reviewed prior guidelines, including the 2013 Korean consensus, and shared their expertise on dosage, injection techniques, and potential complications associated with the use of the novel BoNTA product for facial expression muscles. The recommendations aimed to guide the best practices of the average aesthetic healthcare professional. Results: The panel reached a consensus on various aspects of using the BoNTA product, including recommended injection sites, dosages, and techniques for different aesthetic conditions caused by facial expression muscles. The resulting guideline emphasizes safety and efficacy, with recommendations based on the collective experience of the expert panel. Conclusion: This updated consensus guideline provides practical recommendations from Korean experts on the use of the novel BoNTA product for facial expression muscles. The guidelines will ensure safe and effective treatments while reflecting the latest advancements in the field. Full article
(This article belongs to the Special Issue Botulinum Toxin Application in the Medical Aesthetics Industry)
Show Figures

Figure 1

Back to TopTop